cyrilzakka/clinical-trials huggingface dataset:
Toward Zero Prescribed Opioids for Outpatient General Surgery

Investigators have created an opioid reduction "package" which includes patient education, non-narcotic pain control instructions, and limited (or no) opioid pain prescriptions provided at discharge in an attempt to reduce the number of opioid consumption after outpatient general surgery.

Between November 2019 and July 2021, patients undergoing elective inguinal hernia repair (IHR) or cholecystectomy were enrolled in the study. Patients were divided into three cohorts: Control, opioid sparing (OS), or zero-opioid (ZO). Control patients did not have any intervention; OS patients had an opioid reduction intervention protocol applied (patient education and perioperative multimodal analgesia) and were provided an opioid prescription at discharge; the ZO had the same protocol, however patients were not provided opioid prescriptions at discharge. Two weeks after discharge patients were interviewed to record opioid consumption, pain scores, and level of satisfaction since discharge.

Eligibility Criteria:
Inclusion Criteria:

* Opioid naïve patients
* Age \> 18
* Being scheduled for an outpatient elective inguinal hernia repair or cholecystectomy

Exclusion Criteria:

* Urgent/emergent status
* Previous cholecystostomy tube placement
Study to Evaluate Effectiveness of Aranesp®

The purpose of this study was to evaluate subject preference for Aranesp® administered once monthly (i.e., every 4 weeks (Q4W)) or Procrit® administered once weekly (QW).


Eligibility Criteria:
Inclusion Criteria: - Subjects must have signed written informed consent - Be on Procrit® QW or Q2W for a minimum of 12 weeks - Must currently be on a stable dose of Procrit® (defined as less than 25% change in Procrit® dose over the 4 week period immediately prior to enrollment, with no missed doses) - Have Hgb 10-12 g/dL for at least 4 weeks prior to study start - Have 15 less than GFR less than 89 mL/min/1.73 m2 - Have serum vitamin B12 and folate levels above the lower limits of normal - Transferrin saturation greater than 20% Exclusion Criteria: - Currently receiving investigational erythropoietic agents - Expected to initiate renal replacement therapy (dialysis or transplantation) within 1 year of study start - Have less than 1 year life expectancy
Effect of Testofen on Erectile Function in an Adult Male Population

This is a double blind, randomised, placebo-controlled clinical study with a 12-week participation and 3 groups (2 active groups and 1 placebo group) designed to monitor erectile function symptom severity and the effect Testofen may have on improving erectile function, sexual function, and quality of life.


Eligibility Criteria:
Inclusion Criteria:

* Healthy male adults aged 40-75 years
* Currently in a sexual relationship
* Males with reduced erectile function (Score of \<25 on IIEF)
* BMI ≤ 35
* Able to provide informed consent
* Agree not to change current diet and exercise program while enrolled in this trial
* Agree not to undertake another clinical trial while enrolled in this trial

Exclusion Criteria:

* History of prostate surgery and/or trauma
* Receiving/prescribed treatment for erectile dysfunction, including oral medications, vacuum devices, constrictive devices, injections, or urethral suppositories
* Receiving/prescribed treatment to increase/decrease testosterone levels e.g. androgens/anti androgens
* Receiving/prescribed treatment to increase/decrease nitrate or nitric oxide levels
* Unstable or serious illness (e.g. serious mood disorders, neurological disorders such as MS, kidney disease, liver disease, heart conditions, diabetes, hormone production disorders)\*
* All current malignancies (excluding BCC) or chemotherapy and/or radiotherapy treatment for malignancy within the previous 2 years
* Receiving/prescribed \[e.g., Coumadin or Marevan (warfarin), heparin, dalteparin, enoxaparin) or other anticoagulation therapy (e.g., thromboembolectomy or the use of vena cava filters)
* Active smokers, nicotine use, alcohol, or drug (prescription or illegal substances) abuse
* Chronic past and/or current alcohol use (\>14 alcoholic drinks week)
* Allergic to any of the ingredients in the active or placebo formula
* Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion
* Participants who have participated in any other related clinical study during the past 1 month

a Any participant reporting having been told by their doctor that they have an under or over production of hormones (e.g., testosterone).

\*An unstable illness is any illness that is currently not being treated with a stable dose of medication or is fluctuating in severity. A serious illness is a condition that carries a risk of mortality, negatively impacts quality of life and daily function and/or is burdensome in symptoms and/or treatments.
The PIT-TBI Pilot Study

Damage to the pituitary gland is a frequently overlooked but potentially important complication of traumatic brain injury (TBI). Disorders of the pituitary gland can cause dysfunction of the thyroid, adrenals, ovaries and testes. These disorders may occur immediately or several months after TBI, may delay recovery and may have a significant negative impact on quality of life. TBI is the leading cause of disability and major permanent functional impairment among adults under 45 years of age. Hormonal deficits may contribute to common symptoms experienced by TBI survivors such as fatigue, poor concentration, depression and low exercise capacity. However, the association between hormonal deficits and disability remains uncertain. The primary objective of this pilot study is to assess the feasibility of a larger study that will evaluate the impact of pituitary disorders on neurological disability and functional recovery. The results of this study will provide key findings in the impact of pituitary disorders following TBI, which is a mandatory step prior testing the effect of hormonal replacement therapy in this population in costly clinical trials. If no relationship between pituitary disorders and disability is observed, the investigators' findings will prevent unnecessary, time-consuming and costly hormonal screening and will discourage potentially harmful hormonal therapy.


Eligibility Criteria:
Inclusion Criteria:

* Adult (≥ 18 years old)
* Severe or moderate blunt TBI admitted to the ICU with a Glasgow Coma Scale ≤ 12 following initial resuscitation

Exclusion Criteria:

* Previously diagnosed or suspected pituitary disorder or disease
* Pregnant or lactating woman
* Penetrating TBI
* Solid malignancy with life expectation \<12 months
* Liver Cirrhosis Child C
* Chronic Heart Failure (New York Heart Association class IV)
* End-stage chronic respiratory disease (O2 dependent)
* End-stage renal disease (chronic dialysis or to be expected)
* Neurological conditions influencing functional status (e.g. spinal cord injury, neuromuscular disease, dementia, prior TBI or stroke)
* No fixed address
* Physician refusal
* Brain death
* Unable to return to the study center to attend the follow-up visits
* Admission to the Intensive Care Unit of the participating center \> 24 hours after TBI
Physical Activity on Eye Hand Coordination Post Strabismus Surgery

The aim of this study is to determine the effect of physical activity on eye hand coordination in patient with amblyopia after strabismus surgery.

Eye hand coordination is essential to many of everyday activities. Strabismus not only affect vision but also affect eye hand activities and coordination. Through this study the patients will apply physical therapy sessions to improve eye hand coordination for strabismus amblyopic patient.

Eligibility Criteria:
Inclusion Criteria:

* Patients are both males and females.
* Their age will range from (10-14) years.
* Patients received strabismus operation.
* Patients are suffering from strabismic amblyopia
* Patients are suffering from eye hand coordination problems
* Patients will begin the training program after 2 months of operation.
* All types of strabismus surgery will be included.

Exclusion Criteria:

* Patient who didn't complete the physiotherapy training program for 3 months.
* Muscular disorders that will impair performance during training.
* Any organic lesion in the eye.
* Neurological disorders.
* Malignant conditions.
* Psychiatric illness, severe behavior or cognitive disorders.
* Children who can't understand the therapist's instructions and orders
* Amblyopia which is not related to strabismus condition .
Long-term Outcome of End-stage Renal Disease Patients Treated With Hig-efficiency Hemodiafiltration

A retrospective cohort study was conducted in 66 end-stage renal disease patients who underwent high-efficiency hemodiafiltration technique in King Chulalongkorn Memorial Hospital between 2001-2013 to determine the survival rate as well as other long-term outcome.

Growing evidences suggested the superiority of high-efficiency hemodiafiltration (HDF) which could provide both diffusion and convection in a single therapy compared with the conventional hemodialysis. However, the long-term, upto 10 years, outcome still limited. This retrospective cohort study was conducted in 66 end-stage renal disease patients who underwent high-efficiency hemodiafiltration technique in a single-center, King Chulalongkorn Memorial Hospital, between 2001-2013 to determine the survival rate as well as other long-term outcome

Eligibility Criteria:
Inclusion Criteria:

* Aged 18 years or more
* Be diagnosed end-stage renal disease for more than one year
* Have been regularly received long-term hemodiafiltration for more than 6 months.

Exclusion Criteria:

* Patients who received hemodiafiltration less than 6 months
The Effects of Whole Body Vibration in People With Chronic Stroke

Whole body vibration (WBV) has been found to be useful in promoting bone health and muscle performance in older adults. To date, no study has examined the effects of different WBV frequencies on the properties of the muscle-bone unit in stroke patients. The overall aim of the proposed study is to compare the efficacy of different vibration frequencies on properties of the muscle function and bone turnover among people with chronic stroke.

It is hypothesized that the higher-vibration frequency protocol will lead to significantly better outcomes related to the bone turnover and muscle function.

Whole body vibration (WBV) has been found to be useful in promoting bone health and muscle performance in older adults. To date, no study has examined the effects of different WBV frequencies on the properties of the muscle-bone unit in stroke patients. The overall aim of the proposed study is to compare the efficacy of different vibration frequencies on properties of the muscle function and bone turnover among people with chronic stroke.

It is hypothesized that the higher-vibration frequency protocol will lead to significantly better outcomes related to the bone turnover and muscle function in people with chronic stroke.

Eligibility Criteria:
Inclusion Criteria:

1. a diagnosis of stroke
2. stroke onset \>6 months
3. \>18 years of age
4. able to walk for short distance independently with or without walking aid
5. able to understand simple verbal commands

Exclusion Criteria:

1. neurological conditions other than stroke
2. significant musculoskeletal conditions (e.g. amputations)
3. metal implants in the lower extremity
4. previous fracture of the lower extremity
5. are currently taking bone resorption inhibitors or were taking the same before stroke.
6. significant peripheral vascular disease
7. vestibular disorders
8. pregnancy
9. Other serious illnesses that preclude the person from participating in the study
Reducing Breathlessness With Dronabinol in COPD Patients

This clinical trial examines whether Dronabinol, which contains the synthetic psychoactive compound tetrahydrocannabinol (THC), can alleviate severe breathlessness in patients with severe and very severe chronic obstructive pulmonary disease (COPD).

This study is a randomized, controlled, double-blind, crossover trial evaluating the effectiveness of the pharmaceutical drug Dronabinol in patients with severe and very severe COPD.

The researchers will compare the effects of Dronabinol with a placebo (an identical-looking substance that contains no active drug) to determine if Dronabinol reduces breathlessness in COPD patients.

After enrollment, study subjects will undergo four weeks of treatment with both Dronabinol and the placebo in a blinded and randomized sequence. There is a two-week washout period between treatments. During these treatment phases, subjects will complete questionnaires about their daily experiences of breathlessness and wear a watch that records various health parameters.

The study includes eight visits: the initial enrollment and follow-up checks every two weeks. At these visits, subjects undergo tests for lung function and walking distance, and complete health status questionnaires. Additionally, blood samples for THC levels and hair samples for cortisol analysis are collected.

Eligibility Criteria:
Inclusion Criteria:

* Refractory dyspnea despite optimal treatment
* COPD (GOLD 3,4)
* Breathlessness corresponding to mMRC score ≥ 3
* Informed written consent
* Age ≥ 18 years
* Cognitive relevant, of legal age
* Understands and speaks Danish
* For fertile women defined by amenorrhea for less than 12 months: negative HCG before entry into the trial
* For fertile and sexually active subjects: use of safe contraception during medication intake and 4 weeks after: intrauterine device (IUD) or hormonal contraception (oral contraceptive pill, implant, transdermal patch, vaginal ring or depot injection).

Exclusion Criteria:

* Ongoing infection or exacerbation of COPD within the last month (30 days)
* Regular treatment with THC or CBD within 1 month (30 days)
* Life expectancy less than 3 months (90 days)
* Treatment with medicines that, according to the summary of product characteristics, are strong inhibitors or inducers of CYP3A4, CYP2C9 or CYP2C19
* History of or current evidence of significant medical or psychiatric disorder that is considered by the investigator to put the subject at greater risk of experiencing an adverse event
* Current or past substance abuse where the investigator finds it too risky for the subject to be included in the study
Efficacy of Preoperative Nutritional Support on Postoperative Outcome in Gastric Cancer Patients at Nutritional Risk by NRS-2002

Evaluation of the impact of preoperative nutritional support on clinical outcomes in patients at nutritional risk. The primary endpoint was the complication rate and the second endpoint was the length of stay.


Eligibility Criteria:
Inclusion Criteria:

* clinical diagnosis of gastric cancer surgery preoperative stage

Exclusion Criteria:

* neoadjuvent chemoradiation
* pregnant
* advanced stage
Electronic Triggers: Messaging After A1C EHR Alert

Studying subjects with HbA1C tests \>10 and no follow-up test within 6 months and appointments scheduled in the next 60 days from data run date. Subjects who receive intervention message may be more likely to follow up with their provider to schedule a follow up HbA1C test.


Eligibility Criteria:
Inclusion Criteria:

* MyChart active patients with HbA1C tests \>10 and no follow-up test within 6 months and no appointments scheduled in the next 60 days from data run date

Exclusion Criteria:

* Patients with a scheduled appointment within 60 days from time algorithm is run; hospital encounters; non English or Spanish patients as indicated by primary language in Epic
Impact of a Transportable Customizable and Scalable Sitting Positioning Device on Swallowing Disorders

When the seat is a vehicle for disabled person, postural adaptation methodology is known and, on prescription, there is possibility of financial support for technical posture assists. For people who use a standard seat, a chair for example, there is no satisfactory existing hardware.

A transportable customisable and scalable sitting positioning device (DATP device), to be placed on a standard seat, is a solution that might fit in the home, in specialized foster homes or in institutions for the elderly. Such a device has been developed but earnings on swallowing disorders have to be validated.


Eligibility Criteria:
Inclusion Criteria :

* Present a swallowing disorder authenticated by a score Dysphagia Handicap Index above 11
* Postural disorder authenticated by a score greater than 0 to at least 1 of the following 3 items to MCPAA: retroversion, obliquity and rotation of the pelvis
* Autonomy Conservation compatible with the use of different seats including standard seats
* Signing of informed consent

Exclusion Criteria:

* Postural disorder requiring the use of only one type of installation (wheelchair or hull)
* Spinal stiffness or non-reducible hips (spondylitis, osteosynthesis rod)
* Not included anthropometric dimensions between:

  * Basin with between 39 and 50 cm
  * femoral length between 42 and 52 cm
  * tibial length between 39 and 44 cm (46.5 with femoral recharge), measured with the shoes.
* Pregnant or lactating women
Community Colorectal Cancer Awareness, Research, Education & Screening (C-CARES)

The purpose of this study is to test if including personalization in education materials about colorectal cancer screening is more effective at helping encourage people to complete colorectal cancer screening.


Eligibility Criteria:
Inclusion Criteria:

* Able to understand, read and speak English or Spanish
* Are not up-to-date with colorectal cancer screening
* No symptoms of colorectal cancer
* Not at increased risk for colorectal cancer due to family history or personal high-risk GI syndromes

Exclusion Criteria:

* Symptoms of colorectal cancer
* Family history of colorectal cancer
The Effect of Kinesio Taping Tension on the Pain Threshold and Tolerance

The aim of this study was to investigate the effects of kinesiotape technique applied in different tensions on pain tolerance (PT) of healthy university students. 100 healthy and volunteer male individuals studying at Mugla Sitki Kocman University Faculty of Health Sciences will participate in the research. Study protocol was approved by the ethics committee of Mugla Sitki Kocman University. The study is designed as a randomized, controlled, double-blind study to be performed on 4 groups consisting of 25 individuals in each group (No tension(Placebo), and 50%, 75%, 100% tensions of Kinesiotape). Kinesiotape will be applied over lateral epicondyle of the dominant extremities with diamond shape technique by a KTAI®certified physiotherapist. PT's will be measured with J-Tech algometer before, immediately and 30 minutes after taping by a different physiotherapist who will be blind to taping tension.

Diamond shape banding method will be applied in a way that 4 bands of 2.5 cm width cut kinesio tape ends on top of each other, leaving the lateral epicondyle region exposed while the elbows are slightly flexed in the supine position. In the groups where different tensions will be applied, the middle points of the tapes will be stretched according to the amount of tensions, and the ends will be taped over each other without tension.In the placebo group, the tapes of the tapes will be applied tensionlessly without overlapping each other. Algometer will be used in the assessment of pressure pain threshold and pain tolerance. Pain severity felt at the level of pain threshold and pain tolerance will be evaluated with the Visual Analogue Scale (VAS). All measurements will be made before taping, immediately after taping and 30 minutes after taping, will be repeated 3 times and their average values will be recorded. There will be a 60 second rest period between each trial to avoid temporal sensitization. Each assessment will be performed bilaterally by another physiotherapist who is blind to the band tension and has no experience with the kinesio banding technique.

Eligibility Criteria:
Inclusion Criteria:

* Being a male university student over the age of 18
* Volunteering for the study
* Filling out the informed consent form Not having the knowledge and experience about kinesiotaping before

Exclusion Criteria:

* Being diagnosed with lateral epicondylit and its treatment
* Having any neurological disease or systemic disease that disrupts sense / pain perception (diabetes, rheumatoid arthritis, peripheral vascular disease, etc.)
* Skin sensitivity to elastic banding
* Open wound, ulcer, fungal infection in the area to be taped
* Exposure to upper extremity and / or cervical injury in the past 6 months
A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies

Two part study to evaluate the safety, tolerability, pharmacokinetics, and efficacy (in Part 2 only) of KRP203 in patients undergoing allogeneic hemopoietic stem cell transplant for hematological malignancies


Eligibility Criteria:
Inclusion Criteria

* Patients aged 18 to 65 years, inclusive
* Patients must have a hematological malignancy that as per standard medical practice requires myeloablative conditioning (including short term myeloablative reduced intensity conditioning) followed by allogeneic hematopoetic stem cell transplant

  * Karnofsky Performance status ≥60%.
  * Suitable stem cell source available according to the graft selection algorithm using T-cell replete peripheral stem cells as a graft source

Exclusion Criteria:

* Resting heart rate below 55
* Significant cardiac disease (such as arrhytmia, heart failure) or any significant condition which in the investigators opinion would make the patient ineligible

  * Previous allogeneic HSCT
  * Any drug required that is not compatible with KRP203 (e.g. beta-blockers or anti-thymocyte globulin)
Validation of an Innovative Neonatal Jaundice Detection System (Picterus) in Indonesia

The long-term goal of this project is to establish Picterus as a permanent tool to detect NNJ in the healthcare services of Indonesia. Offering early detection and therefore, timely treatment to NNJ, will substantially improve neonatal health and directly work towards the Sustainable Development Goal 3.2.2, reduce neonatal mortality. The study as the following specific subgoals:

* Demonstrate that Picterus system performs accurately in Indonesian newborns
* Ensure that Picterus is in line with users' needs in Indonesia

The long-term goal of this project is to establish Picterus as a permanent tool to detect NNJ in the healthcare services of Indonesia. Offering early detection and therefore, timely treatment to NNJ, will substantially improve neonatal health and directly work towards the Sustainable Development Goal 3.2.2, reduce neonatal mortality. The study as the following specific subgoals:

* Demonstrate that Picterus system performs accurately in Indonesian newborns
* Ensure that Picterus is in line with users' needs in Indonesia

Eligibility Criteria:
Inclusion Criteria:

- Infants born with gestational age ≥37 weeks Birth weight ≥2000g and ≤4500g Age 1 - 14 days

Exclusion Criteria:

- Infants transferred to the pediatric ward for advanced treatment. Infants with a skin rash or other disease that affects the skin where measurements are performed.

Infants that receive or have received phototherapy in the last 24 hours. Infants with an inborn disease